Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 71 to 80 of 281 total matches.
Tarlatamab (Imdelltra) for Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024 (Issue 1706)
common.
Life-threatening neurotoxicity and cytokine release syndrome
can occur.
Drug Interactions ...
Tarlatamab-dlle (Imdelltra – Amgen), a first-in-class
bispecific delta-like ligand 3 (DLL3)-directed CD3
T-cell engager, has received accelerated approval
from the FDA for treatment of extensive-stage
small cell lung cancer (SCLC) in adults who had
disease progression on or after platinum-based
chemotherapy. It is the first bispecific DLL3-directed
CD3 T-cell engager to be approved in the US for this
indication. Most patients with SCLC have a response
to initial treatment, but progression generally
occurs within a few months and overall survival is
usually less than 8 months....
Med Lett Drugs Ther. 2024 Jul 8;66(1706):e113-4 doi:10.58347/tml.2024.1706c | Show Introduction Hide Introduction
Etrasimod (Velsipity) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
, and atrioventricular conduction delays may occur.
Drug Interactions: Concurrent use of moderate or strong ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator etrasimod (Velsipity – Pfizer) has been
approved by the FDA for treatment of moderately to
severely active ulcerative colitis in adults. It is the
second oral S1P receptor modulator to be approved
in the US for this indication; ozanimod (Zeposia) was
the first.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):187-9 doi:10.58347/tml.2023.1690b | Show Introduction Hide Introduction
Lenacapavir (Sunlenca) for Multidrug-Resistant HIV
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
in rats and rabbits, high doses of the drug were not
associated with fetal toxicity.
DRUG INTERACTIONS ...
The FDA has approved oral and injectable
formulations of the HIV-1 capsid inhibitor lenacapavir
(Sunlenca – Gilead) for use with other antiretroviral
drugs to treat multidrug-resistant HIV-1 infection
(MDR-HIV) in heavily treatment-experienced adults
whose current regimen is failing. Lenacapavir is the
third drug to be approved exclusively for treatment
of MDR-HIV; the intravenously administered CD4-directed antibody ibalizumab-uiyk (Trogarzo) and the
orally administered HIV-1 gp120-directed attachment
inhibitor fostemsavir (Rukobia) were approved earlier.
Med Lett Drugs Ther. 2023 May 1;65(1675):68-70 doi:10.58347/tml.2023.1675c | Show Introduction Hide Introduction
Vonoprazan (Voquezna) for Erosive Esophagitis
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
hyperplastic polyps with chronic bleeding.9
DRUG INTERACTIONS ― Vonoprazan, like traditional
PPIs ...
The FDA has approved vonoprazan (Voquezna –
Phathom), a potassium-competitive acid blocker, for
healing and maintenance of healing of all grades of
erosive esophagitis and relief of associated heartburn in adults. Vonoprazan is also available copackaged
with amoxicillin (Voquezna Dual Pak) and with
amoxicillin and clarithromycin (Voquezna Triple Pak)
for treatment of Helicobacter pylori infection in adults.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):203-5 doi:10.58347/tml.2023.1692b | Show Introduction Hide Introduction
Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
: Shorter treatment duration and fewer drug
interactions than oral fluconazole, but much more expensive ...
The FDA has approved oteseconazole (Vivjoa –
Mycovia), a new oral azole antifungal, to reduce the incidence
of recurrent vulvovaginal candidiasis (RVVC)
in females with a history of RVVC. Oteseconazole is
the first drug to be approved in the US specifically for
treatment of RVVC.
Turmeric Supplements
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019 (Issue 1585)
Turmeric Supplements
DRUG INTERACTIONS — Curcumin inhibits CYP3A4,
1A2, and 2D6 and the efflux ...
Turmeric is a spice derived from the Curcuma longa
plant. Dietary supplements and foods containing
turmeric are widely promoted for relief of pain
and to improve joint mobility, immunity, digestion,
cardiovascular health, depression, anxiety, memory,
and cognition.
Capivasertib (Truqap) for Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
be monitored before starting
capivasertib and periodically during treatment.
DRUG INTERACTIONS ― Capivasertib ...
The oral kinase inhibitor capivasertib (Truqap –
AstraZeneca), a first-in-class AKT inhibitor, has
been approved by the FDA for use in combination
with the selective estrogen receptor degrader (SERD)
fulvestrant (Faslodex, and generics) for treatment of
hormone receptor (HR)-positive, human epidermal
growth factor receptor 2 (HER2)-negative, locally
advanced or metastatic breast cancer in adults with
one or more PIK3CA/AKT1/PTEN-alterations who had
disease progression on at least one endocrine-based
regimen for metastatic disease or recurrence on or
within 12 months of completing...
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e32-3 doi:10.58347/tml.2024.1696e | Show Introduction Hide Introduction
Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
, vomiting,
constipation, abdominal pain, and dizziness are most common.
Drug Interactions: Use with strong ...
Resmetirom (Rezdiffra – Madrigal), a thyroid hormone
receptor-beta agonist, has received accelerated
approval from the FDA for treatment of noncirrhotic
nonalcoholic steatohepatitis (NASH) with moderate
to advanced fibrosis in adults. NASH has recently
been renamed metabolic dysfunction-associated
steatohepatitis (MASH). Resmetirom is the first drug
to be approved in the US for this indication.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):65-6 doi:10.58347/tml.2024.1701a | Show Introduction Hide Introduction
Trofinetide (Daybue) for Rett Syndrome (online only)
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024 (Issue 1706)
, fatigue, and
weight loss have been reported.
Drug Interactions: Use with sensitive OATP1B1/3 substrates ...
Trofinetide (Daybue – Acadia), a synthetic analog
of glycine-proline-glutamate, has been approved by
the FDA for treatment of Rett syndrome in patients
≥2 years old. It is the first drug to be approved in the
US for treatment of Rett syndrome.
Med Lett Drugs Ther. 2024 Jul 8;66(1706):e115-6 doi:10.58347/tml.2024.1706d | Show Introduction Hide Introduction
Repotrectinib (Augtyro) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
can occur. Repotrectinib does not cause clinically significant QT-interval prolongation.
Drug ...
The FDA has approved the oral tyrosine kinase
inhibitor repotrectinib (Augtyro – BMS) for treatment
of locally advanced or metastatic ROS1-positive
non-small cell lung cancer (NSCLC) in adults.
Repotrectinib is the third oral tyrosine kinase inhibitor
to be approved for this indication in the US; crizotinib
(Xalkori) and entrectinib (Rozlytrek) were approved
earlier.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e36-7 doi:10.58347/tml.2024.1696g | Show Introduction Hide Introduction